Regencell Bioscience Holdings Limited (RGC)

NASDAQ: RGC · Real-Time Price · USD

27.23

+2.16 (8.62%)

At close: Feb 6, 2026, 4:00 PM EST

27.64

+0.41 (1.51%)

After-hours: Feb 6, 2026, 7:53 PM EST

RGC Income Statement

Financials in millions USD. Fiscal year is July - June.

Millions USD. Fiscal year is Jul - Jun.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '25 Jun 30, 2025	Jun '24 Jun 30, 2024	Jun '23 Jun 30, 2023	Jun '22 Jun 30, 2022	Jun '21 Jun 30, 2021
Selling, General & Admin	2.82	3.78	4.69	5.11	0.94
Research & Development	0.95	0.95	1.58	2.51	0.44
Operating Expenses	3.77	4.74	6.27	7.62	1.38
Operating Income	-3.77	-4.74	-6.27	-7.62	-1.38
EBT Excluding Unusual Items	-3.77	-4.74	-6.27	-7.62	-1.38
Other Unusual Items	0.19	0.37	0.21	0.02	0.03
Pretax Income	-3.58	-4.36	-6.06	-7.59	-1.35
Earnings From Continuing Operations	-3.58	-4.36	-6.06	-7.59	-1.35
Minority Interest in Earnings	-	0.06	0.19	0.15	-
Net Income	-3.58	-4.3	-5.87	-7.45	-1.35
Net Income to Common	-3.58	-4.3	-5.87	-7.45	-1.35
Shares Outstanding (Basic)	494	494	494	487	380
Shares Outstanding (Diluted)	494	494	494	487	380
Shares Change (YoY)	-	-	1.62%	28.06%	-
EPS (Basic)	-0.01	-0.01	-0.01	-0.02	-0.00
EPS (Diluted)	-0.01	-0.01	-0.01	-0.02	-0.00
Free Cash Flow	-3.27	-4.01	-4.99	-6.05	-0.77
Free Cash Flow Per Share	-0.01	-0.01	-0.01	-0.01	-0.00
EBITDA	-3.69	-4.43	-5.98	-7.47	-1.35
D&A For EBITDA	0.08	0.31	0.29	0.15	0.03
EBIT	-3.77	-4.74	-6.27	-7.62	-1.38
Advertising Expenses	-	1	0.03	0.03	-

Updated Jun 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q